5:12 PM
 | 
Oct 11, 2013
 |  BC Extra  |  Company News

Amarin falls after FDA reviewers cautious on Vascepa expansion

Amarin Corp. plc (NASDAQ:AMRN) fell $1.28 (20%) to $5.09 on Friday after FDA reviewers questioned whether the agency should approve hypertriglyceridemia drug Vascepa icosapent ethyl for a broader population without cardiovascular data showing a benefit. The reviewers said FDA "has historically considered granting approval for lipid-altering drugs...

Read the full 223 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >